Disseminated Intravascular Coagulation

Disseminated Intravascular Coagulation (DIC) – High‑Yield Study Guide

Definition

Disseminated intravascular coagulation (DIC) is an acquired clinicopathologic syndrome characterized by systemic activation of coagulation leading to widespread intravascular fibrin formation, consumption of platelets and coagulation factors, and secondary activation of fibrinolysis. This results in a paradoxical combination of microvascular thrombosis and bleeding diathesis, often in the setting of a severe underlying disorder such as sepsis, trauma, malignancy, or obstetric complications.^[1]

Epidemiology and Etiology

DIC is not a primary disease but a complication of diverse critical illnesses. Incidence varies widely depending on the population and criteria used.

• Sepsis-associated DIC: Most frequent form, especially in gram‑negative and some gram‑positive bacterial infections; a major contributor to multiple organ dysfunction and mortality in sepsis.^{[2], [3]}
• Trauma and massive tissue injury: Polytrauma, burns, crush injuries.
• Malignancy: Particularly acute promyelocytic leukemia (APL), metastatic adenocarcinoma, mucin‑producing tumors.
• Obstetric complications: Placental abruption, amniotic fluid embolism, severe preeclampsia/HELLP syndrome, retained dead fetus, severe postpartum hemorrhage.^{[4], [5]}
• Severe transfusion reactions: ABO incompatibility, massive transfusion.
• Liver failure and heat stroke and certain vascular anomalies.
• Other triggers: Severe systemic inflammation, shock states, and rare severe infections after minor procedures (e.g., gynecologic infections) can precipitate fulminant DIC.^[6]

Pathophysiology

DIC develops when the balance between procoagulant, anticoagulant, and fibrinolytic systems is profoundly disrupted. It is best understood as a thromboinflammatory syndrome in which inflammation, coagulation, and endothelial injury amplify one another.^{[1], [2]}

• Triggering event: Underlying condition (e.g., sepsis, trauma) induces systemic inflammatory response with release of cytokines (TNF‑α, IL‑1, IL‑6), endotoxin, and DAMPs/PAMPs.
• Massive tissue factor (TF) expression:
  • Monocytes, macrophages, and injured endothelium express TF, activating the extrinsic coagulation pathway.
  • TF–factor VIIa complex drives thrombin generation and fibrin formation.
• Endotheliopathy:
  • Endothelial cells lose their antithrombotic phenotype: decreased thrombomodulin, decreased endothelial protein C receptor, reduced heparan sulfate, and increased expression of adhesion molecules.
  • Endothelial damage promotes platelet adhesion/aggregation and amplifies intravascular coagulation.^[2]
• Consumption of platelets and coagulation factors:
  • Widespread fibrin and platelet microthrombi consume platelets, fibrinogen, and multiple clotting factors.
  • This results in thrombocytopenia and prolonged PT/aPTT.
• Impaired physiologic anticoagulant pathways:
  • Reduction of antithrombin, protein C, and protein S due to consumption, impaired synthesis, and endothelial dysfunction.
  • This loss of anticoagulant function further accelerates thrombin generation.^[1]
• Dysregulated fibrinolysis:
  • Initial activation of fibrinolysis leads to elevated D‑dimer and fibrin degradation products (FDPs).
  • Plasminogen activator inhibitor‑1 (PAI‑1) may become elevated, leading to suppressed fibrinolysis in many sepsis‑associated cases, thus favoring persistent fibrin deposition.
• Organ dysfunction:
  • Microvascular fibrin thrombi cause tissue ischemia, contributing to multiorgan dysfunction (kidney, lungs, liver, CNS, GI tract).

Clinical Presentation

Presentations range from subclinical laboratory abnormalities to fulminant bleeding and multiorgan failure. Clinical features depend on the speed of onset, severity, and underlying cause.

Common Symptoms and Signs

• Bleeding manifestations (especially in acute DIC):
  • Oozing from venipuncture sites, arterial lines, central lines.
  • Mucosal bleeding: epistaxis, gingival bleeding, hematuria.
  • Gastrointestinal bleeding, menorrhagia, postpartum hemorrhage.
  • Ecchymoses, petechiae, purpura.
  • Severe cases: intracranial hemorrhage, life‑threatening hemorrhage after minor procedures.^[6]
• Thrombotic manifestations (especially in more chronic/low‑grade DIC such as malignancy‑associated):
  • Digital ischemia and necrosis.
  • Venous thromboembolism (DVT, PE).
  • Arterial thrombosis, organ ischemia (kidney, liver, mesentery).
• Organ dysfunction due to microvascular thrombosis and shock:
  • Renal: oliguria, AKI.
  • Pulmonary: hypoxemia, ARDS.
  • Hepatic: jaundice, elevated transaminases, coagulopathy.
  • Neurologic: confusion, coma, focal deficits.
  • Cardiovascular: hypotension, tachycardia, shock.

Acute vs Chronic DIC

• Acute DIC: Rapid onset, typically in sepsis, trauma, or obstetric catastrophes. Dominated by bleeding and acute organ failure; labs show marked abnormalities.
• Chronic (compensated) DIC: More indolent, often in solid tumors or large aortic aneurysms. Thrombosis may predominate; laboratory abnormalities may be mild or fluctuating.

Diagnosis

DIC is a clinical–laboratory diagnosis, based on evidence of systemic coagulation activation with consumption of platelets and clotting factors, in the context of a compatible underlying disorder. Several scoring systems exist, including those from the International Society on Thrombosis and Haemostasis (ISTH), the Japanese Association for Acute Medicine (JAAM), and the Japanese Ministry of Health, Labour and Welfare (JMHLW).^{[7], [8]}

Key Laboratory Findings

• Thrombocytopenia: Platelets often <100 × 10⁹/L; trend over time is important.
• Prolonged PT/INR and aPTT: Reflect consumption of clotting factors.
• Low fibrinogen: <1.0–1.5 g/L in acute DIC; however, in sepsis, fibrinogen may be initially normal or elevated due to acute‑phase response, so falling trends are key.
• Elevated fibrin-related markers:
  • High D‑dimer and fibrin degradation products (FDPs) are highly sensitive for DIC; a normal D‑dimer makes DIC unlikely.
• Peripheral blood smear:
  • Schistocytes (fragmented RBCs) may be present but are often less numerous than in primary thrombotic microangiopathies.
• Reduced natural anticoagulants: Low antithrombin and protein C levels are typical in sepsis‑associated DIC.^[1]

ISTH DIC Scoring System (Concept)

The ISTH overt DIC score uses platelet count, elevated fibrin‑related markers (e.g., D‑dimer/FDP), prolonged PT, and fibrinogen level to classify patients as having "overt" vs "non‑overt" DIC. A score ≥5 is suggestive of overt DIC in the appropriate clinical context.^[7]

Differential Diagnosis

• Thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies.
• Isolated severe liver disease–related coagulopathy.
• Heparin-induced thrombocytopenia (HIT).
• Vitamin K deficiency or warfarin effect.
• Massive transfusion–associated coagulopathy.

Management

Management of DIC focuses on treating the underlying cause, supporting organ function, and balancing bleeding and thrombosis risk. There is global variability and uncertainty in practice, highlighting the need for individualized, context‑specific strategies.^[7]

1. Treat the Underlying Disorder

• Sepsis: Early appropriate antibiotics, source control, hemodynamic resuscitation; DIC resolution strongly correlates with improved survival in sepsis‑associated DIC.^[3]
• Obstetric causes: Deliver the placenta/fetus in placental abruption, manage HELLP and preeclampsia, control postpartum hemorrhage, treat amniotic fluid embolism supportively.^{[4], [5]}
• Malignancy: Treat underlying cancer (chemotherapy, ATRA for APL, etc.).
• Trauma: Early hemorrhage control, damage‑control resuscitation.

2. Hemostatic Support (When Bleeding or High‑Risk Procedures)

Transfusion support is tailored to clinical bleeding and laboratory values.

• Platelet transfusion:
  • Indicated in significant bleeding or prior to invasive procedures when platelet count is low (e.g., <50 × 10⁹/L in bleeding patients; higher thresholds in neurosurgery/ocular procedures).
• Fresh frozen plasma (FFP):
  • Provides multiple clotting factors; used in patients with active bleeding and prolonged PT/aPTT or prior to procedures.
• Cryoprecipitate or fibrinogen concentrate:
  • Used to correct hypofibrinogenemia (e.g., fibrinogen <1.5–2.0 g/L), especially in obstetric DIC or massive hemorrhage.
• Red blood cell transfusion:
  • Given to maintain adequate oxygen delivery (e.g., hemoglobin around 7–8 g/dL, individualized to clinical context).

3. Anticoagulant Therapy

Because thrombosis and bleeding coexist, anticoagulation must be individualized.

• Heparin (unfractionated or LMWH):
  • May be considered in patients with predominant thrombotic manifestations, chronic DIC, or extensive microvascular thrombosis (e.g., purpura fulminans), provided bleeding risk is controlled.
  • Low‑dose prophylactic heparin may be used in many critically ill DIC patients to reduce VTE risk when not actively bleeding.
• Antithrombin concentrates and recombinant thrombomodulin:
  • Investigated in sepsis‑associated DIC, but evidence is inconsistent and these therapies are not universally adopted; use depends on local guidelines and availability.^{[1], [9]}
• Experimental/adjunctive approaches:
  • Granulocyte and monocyte adsorption or other blood purification techniques have been studied as adjuncts in sepsis to modulate hyperinflammation and coagulopathy, but evidence remains limited.^[10]

4. Avoidance of Harm

• Avoid prophylactic transfusion solely based on lab numbers without bleeding or procedural indication.
• Avoid unnecessary invasive procedures in unstable coagulopathy.
• Avoid agents that worsen bleeding (e.g., unnecessary antiplatelets/anticoagulants) unless clearly indicated for thrombosis.

5. Monitoring and Prognosis

• Serial labs: Platelet count, PT/INR, aPTT, fibrinogen, D‑dimer/FDP, and organ function tests should be trended.
• DIC resolution: In sepsis‑associated DIC, improvement in DIC scores and laboratory parameters is associated with reduced mortality, supporting DIC resolution as a surrogate endpoint in research and a positive prognostic sign in practice.^[3]
• Prognosis is primarily determined by the underlying condition and degree of organ failure.

Key Clinical Pearls for Medical Students

• DIC is always secondary: Always search for and aggressively manage the underlying cause (e.g., sepsis, trauma, malignancy, obstetric emergency).
• Think "bleeding + clotting": The hallmark is simultaneous bleeding tendency and microvascular/venous thrombosis with lab evidence of consumption coagulopathy.
• Lab triad: Thrombocytopenia, prolonged PT/aPTT, low or falling fibrinogen, and markedly elevated D‑dimer are classic.
• D‑dimer is very sensitive: A normal D‑dimer makes DIC unlikely in a sick patient; high D‑dimer alone is nonspecific but supports DIC in the right context.
• Use scoring systems: ISTH and other DIC scores help standardize diagnosis and assess severity; they are widely used in research and practice worldwide.^{[7], [8]}
• Acute vs chronic DIC: Acute DIC (e.g., in sepsis/obstetrics) tends to present with bleeding and profound lab abnormalities; chronic DIC (e.g., in malignancy) may present more with thrombosis.
• Transfuse for bleeding, not numbers: Platelets, FFP, and cryoprecipitate are guided by bleeding and procedural risk rather than lab thresholds alone.
• Heparin when thrombosis predominates: Consider low‑dose heparin in chronic or predominantly thrombotic DIC if bleeding is controlled.
• DIC in obstetrics: Think of placental abruption, HELLP, and severe postpartum hemorrhage, where rapid correction of hypofibrinogenemia and source control (delivery/uterine management) are critical.^{[4], [5]}
• Sepsis-associated DIC is common and deadly: Endothelial dysfunction, impaired anticoagulant pathways, and fibrinolysis suppression are central; improving DIC correlates with better outcomes.^{[2], [3]}
• Always rule out TTP/TMAs: Presence of severe microangiopathic hemolytic anemia with neurologic and renal involvement should prompt consideration of TTP, which requires urgent plasma exchange, distinct from DIC management.

Summary

DIC is a dynamic, acquired coagulopathy driven by systemic activation of coagulation and profound disturbance of anticoagulant and fibrinolytic systems. It presents with a spectrum from isolated laboratory abnormalities to catastrophic bleeding and multiorgan failure. Diagnosis relies on clinical context, characteristic lab findings, and validated scoring systems. Management is centered on treating the underlying cause, providing judicious hemostatic support, and carefully balancing bleeding and thrombosis risks. Understanding the pathophysiologic interplay between inflammation, coagulation, and endothelial injury is crucial for grasping both the clinical manifestations and the rationale for current and emerging therapies.^{[1], [7]}